Home > Healthcare > Medical Devices > Diagnostic Devices > Thrombosis and Hemostasis Biomarkers Market

Thrombosis and Hemostasis Biomarkers Market Share

Report ID: GMI12202
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Thrombosis and Hemostasis Biomarkers Market Share

The market is dominated by leading biotechnology and pharmaceutical firms, driven by high demand for accurate diagnostics and precision treatments in cardiovascular care. Major players leverage robust biomarker portfolios, comprehensive diagnostic assays, and innovative therapeutic options to secure significant market positions. Strategic moves like mergers, acquisitions, and collaborations with research institutes enhance their capabilities and extend market reach across diverse applications, including cardiology, oncology, and autoimmune conditions. Additionally, focused investment in R&D enables these companies to innovate biomarker-based solutions, addressing unmet needs in early diagnosis and personalized medicine.

Thrombosis and Hemostasis Biomarkers Market Companies

Major players operating in the thrombosis and hemostasis biomarkers industry are:

Abbott Laboratories
ARUP Laboratories
Biomedica Diagnostics
BioMerieux
Cincinnati Children's Hospital Medical Center
Cleveland Clinic Laboratories
Diazyme Laboratories
F. Hoffmann-La Roche
HORIBA
Mayo Clinic Laboratories
QuidelOrtho
Siemens Healthineers
Thermo Fisher Scientific
Werfen

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global thrombosis and hemostasis biomarkers industry was valued at USD 5.2 billion in 2023 and is estimated to grow at a CAGR of over 5.8% from 2024 to 2032, driven by rising incidences of cardiovascular and clotting disorders.

The reagents and consumables segment dominated the market with USD 3.3 billion in 2023 due to their pivotal role in diagnostic and research applications, including assay kits, chemicals, buffers, and other essential reagents.

The U.S. thrombosis and hemostasis biomarkers market is expected to grow at a 5.8% CAGR, reaching USD 3 billion by 2032, driven by high rates of cardiovascular disease.

Major players in the industry include Abbott Laboratories, ARUP Laboratories, Biomedica Diagnostics, BioMerieux, Cincinnati Children's Hospital Medical Center, Cleveland Clinic Laboratories, Diazyme Laboratories, F. Hoffmann-La Roche, HORIBA, Mayo Clinic Laboratories, and QuidelOrtho.